{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:44:08Z","timestamp":1792601048417,"version":"4.5.0"},"reference-count":48,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T00:00:00Z","timestamp":1792281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T00:00:00Z","timestamp":1792281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"This study was sponsored by Johnson & Johnson"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psoriasis and Psoriatic Arthritis\u00ae"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Icotrokinra, a targeted oral peptide that precisely blocks the interleukin-23 receptor, is approved to treat adult and pediatric (\u226512 years, \u226540\u00a0kg) patients with moderate-to-severe plaque psoriasis (PsO).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Assess psoriatic arthritis (PsA)\u2013specific outcomes through Week (W) 16 in a subgroup of phase-3 study participants with moderate-to-severe plaque PsO and self-reported medical history of PsA (PsO+PsA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Post-hoc analyses pooled data from ICONIC-LEAD and ICONIC-ADVANCE 1 and 2 among PsO+PsA participants randomized to once-daily icotrokinra 200\u00a0mg or placebo through W16. PsA-specific outcomes included mean change from baseline and \u226550% improvement in Patient\u2019s Global Assessment (PtGA) of PsA disease activity and Patient\u2019s Assessment of PsA Pain, and percent change from baseline in modified Nail Psoriasis Severity Index (mNAPSI).\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      values are nominal.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Analyses included 216 participants (149 icotrokinra, 67 placebo). At W8, icotrokinra-treated participants reported greater improvements vs placebo in PtGA of PsA disease activity (\u221218.5 vs \u22124.8;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) and PsA Pain (\u221217.1 vs \u22124.6;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001), with improvement sustained at W16 (\u221219.2 vs \u22120.8;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001; \u221219.5 vs \u22127.8;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.003). At W16, greater proportions of icotrokinra-treated vs placebo-treated participants achieved \u226550% improvement in PtGA of PsA disease activity (47.0% vs 10.7%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) and PsA Pain (45.5% vs 16.1%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). At W16, icotrokinra improved mNAPSI by 41.6% (vs 118.6% worsening with placebo;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). Adverse event rates were similar between icotrokinra and placebo.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Icotrokinra demonstrated early, substantial improvements in participant-reported PsA activity and PsA Pain, and nail psoriasis, with a favorable safety profile through W16 in participants with PsO+PsA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/24755303261494526","type":"journal-article","created":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T13:35:41Z","timestamp":1792330541000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Icotrokinra, a Targeted Oral Peptide, in Participants With Moderate-to-Severe Plaque Psoriasis and Self-Reported Psoriatic Arthritis: Results From a Pooled Analysis of the Phase 3 ICONIC-LEAD, ICONIC-ADVANCE 1, and ICONIC-ADVANCE 2 Trials"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6462-4280","authenticated-orcid":false,"given":"Iain B.","family":"McInnes","sequence":"first","affiliation":[{"name":"University of Glasgow"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Stein Gold","sequence":"additional","affiliation":[{"name":"Henry Ford Health System"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Bissonnette","sequence":"additional","affiliation":[{"name":"Innovaderm Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4705-5303","authenticated-orcid":false,"given":"Mark G.","family":"Lebwohl","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofelia","family":"Reyes-Servin","sequence":"additional","affiliation":[{"name":"Johnson & Johnson"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7291-1272","authenticated-orcid":false,"given":"Joseph","family":"Cafone","sequence":"additional","affiliation":[{"name":"Johnson & Johnson"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Wen","family":"Yang","sequence":"additional","affiliation":[{"name":"Johnson & Johnson"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumya D.","family":"Chakravarty","sequence":"additional","affiliation":[{"name":"Johnson & Johnson"},{"name":"Drexel University College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Iaconangelo","sequence":"additional","affiliation":[{"name":"Johnson & Johnson"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Li","sequence":"additional","affiliation":[{"name":"Johnson & Johnson"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasneam","family":"Shagroni","sequence":"additional","affiliation":[{"name":"Johnson & Johnson"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karissa","family":"Lozenski","sequence":"additional","affiliation":[{"name":"Johnson & Johnson"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April W.","family":"Armstrong","sequence":"additional","affiliation":[{"name":"University of California Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[{"name":"UT Southwestern Medical Center and O'Donnell School of Public Health"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,10,18]]},"reference":[{"key":"e_1_3_8_2_2","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.17-1-65"},{"key":"e_1_3_8_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557"},{"key":"e_1_3_8_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.09.019"},{"key":"e_1_3_8_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.10.021"},{"key":"e_1_3_8_6_2","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X241295920"},{"key":"e_1_3_8_7_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1331217"},{"key":"e_1_3_8_8_2","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2025.2519525"},{"key":"e_1_3_8_9_2","unstructured":"STELARA (Ustekinumab) Injection for Subcutaneous Use. Prescribing Information. Janssen Biotech Inc.; 2025. Accessed April 14 2026. https:\/\/www.jnjlabels.com\/package-insert\/product-monograph\/prescribing-information\/STELARA-pi.pdf"},{"key":"e_1_3_8_10_2","unstructured":"TREMFYA\u00ae (Guselkumab) Injection for Subcutaneous Use. Prescribing Information. Janssen Biotech Inc.; 2025. Accessed April 14 2026. https:\/\/www.jnjlabels.com\/package-insert\/product-monograph\/prescribing-information\/TREMFYA-pi.pdf"},{"key":"e_1_3_8_11_2","unstructured":"SKYRIZI\u00ae (Risankizumab-rzaa) Injection for Subcutaneous or Intravenous Use. Prescribing information AbbVie; 2026. Accessed April 14 2026. https:\/\/www.rxabbvie.com\/pdf\/skyrizi_pi.pdf"},{"key":"e_1_3_8_12_2","unstructured":"ILUMYA\u2122 (tildrakizumab-asmn) injection for subcutaneous use. Prescribing Information. Sun Pharmaceutical Industries. Inc; 2025. Accessed April 14 2026. https:\/\/www.ilumya.com\/Sun_Pharma_ILUMYA_US_Prescribing_Information_.pdf"},{"key":"e_1_3_8_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/jan.13818"},{"key":"e_1_3_8_14_2","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S242336"},{"key":"e_1_3_8_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-67371-5"},{"key":"e_1_3_8_16_2","volume-title":"ICOTYDE\u2122 (Icotrokinra) Tablets, for Oral Use. Prescribing Information","year":"2026","unstructured":"ICOTYDE\u2122 (Icotrokinra) Tablets, for Oral Use. Prescribing Information. Janssen Biotech, Inc; 2026. Accessed April 14, 2026. https:\/\/www.jnjlabels.com\/package-insert\/product-patient-information\/ICOTYDE-medication-guide.pdf"},{"key":"e_1_3_8_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2504187"},{"key":"e_1_3_8_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01576-4"},{"key":"e_1_3_8_19_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100857"},{"key":"e_1_3_8_20_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.200928"},{"key":"e_1_3_8_21_2","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2013.865009"},{"issue":"4","key":"e_1_3_8_22_2","first-page":"238","article-title":"Severe psoriasis\u2013oral therapy with a new retinoid","volume":"157","author":"Fredriksson T","year":"1978","unstructured":"Fredriksson T, Pettersson U. Severe psoriasis\u2013oral therapy with a new retinoid. Dermatologica (Basel). 1978;157(4):238-244.","journal-title":"Dermatologica (Basel)"},{"issue":"1","key":"e_1_3_8_23_2","first-page":"123","article-title":"The modified nail psoriasis severity index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis","volume":"34","author":"Cassell SE","year":"2007","unstructured":"Cassell SE, Bieber JD, Rich P, et al. The modified nail psoriasis severity index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. J Rheumatol. 2007;34(1):123-129.","journal-title":"J Rheumatol"},{"key":"e_1_3_8_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.041"},{"issue":"8","key":"e_1_3_8_25_2","first-page":"793","article-title":"The static Physician's global assessment of genitalia: a clinical outcome measure for the severity of genital psoriasis","volume":"16","author":"Merola JF","year":"2017","unstructured":"Merola JF, Bleakman AP, Gottlieb AB, et al. The static Physician's global assessment of genitalia: a clinical outcome measure for the severity of genital psoriasis. J Drugs Dermatol. 2017;16(8):793-799.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_8_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2010.384"},{"key":"e_1_3_8_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdds.2015.07.004"},{"key":"e_1_3_8_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-017-0212-3"},{"key":"e_1_3_8_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"e_1_3_8_30_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.201681"},{"key":"e_1_3_8_31_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.048975"},{"key":"e_1_3_8_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380602"},{"key":"e_1_3_8_33_2","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2024.2385020"},{"key":"e_1_3_8_34_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.201471"},{"key":"e_1_3_8_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.40726"},{"key":"e_1_3_8_36_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225531"},{"key":"e_1_3_8_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02379-9"},{"key":"e_1_3_8_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkaa033"},{"key":"e_1_3_8_39_2","doi-asserted-by":"publisher","DOI":"10.5114\/reum.2018.80718"},{"key":"e_1_3_8_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.08.026"},{"key":"e_1_3_8_41_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221019"},{"key":"e_1_3_8_42_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221048"},{"key":"e_1_3_8_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)30265-8"},{"key":"e_1_3_8_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)30263-4"},{"key":"e_1_3_8_45_2","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/3nuz51"},{"key":"e_1_3_8_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03971-6"},{"key":"e_1_3_8_47_2","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2500155"},{"key":"e_1_3_8_48_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308713"},{"key":"e_1_3_8_49_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1332432"}],"container-title":["Journal of Psoriasis and Psoriatic Arthritis\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24755303261494526","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/24755303261494526","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24755303261494526","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:18:09Z","timestamp":1792599489000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/24755303261494526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,18]]},"references-count":48,"alternative-id":["10.1177\/24755303261494526"],"URL":"https:\/\/doi.org\/10.1177\/24755303261494526","relation":{},"ISSN":["2475-5303","2475-5311"],"issn-type":[{"value":"2475-5303","type":"print"},{"value":"2475-5311","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,18]]},"article-number":"24755303261494526"}}